Eivind Berge

TL;DR: For the types of patient recruited in IST-3, despite the early hazards, thrombolysis within 6 h improved functional outcome and benefit did not seem to be diminished in elderly patients.

TL;DR: Thrombolytic therapy, mostly administered up to six hours after ischaemic stroke, significantly reduced the proportion of participants who were dead or dependent at three to six months after stroke and increased the risk of symptomatic intracranial haemorrhage.

TL;DR: The evidence indicates that intravenous rt-PA increased the proportion of patients who were alive with favourable outcome and alive and independent at final follow-up, which strengthens previous evidence to treat patients as early as possible after acute ischaemic stroke, although some patients might benefit up to 6 h after stroke.

TL;DR: There was no indication that careful blood-pressure lowering treatment with the angiotensin-receptor blocker candesartan is beneficial in patients with acute stroke and raised blood pressure and there was no evidence of a differential effect in any of the prespecified subgroups.

TL;DR: The European Stroke Organisation (ESO) guidelines provide evidence-based recurrence guidelines for patients with acute ischaemic stroke as mentioned in this paper, where intrvenous thrombolysis is the only approved systemic reperfusion treatment.